Korea's Boryung Pharma Seeking MNCs To Sell Hypertension Product Abroad
This article was originally published in The Pink Sheet Daily
Boryung hopes to find alternatives like out-licensing for Kanarb in order to get around the expense of meeting EU and U.S. manufacturing standards.
You may also be interested in...
SEOUL - South Korea's local pharmas are clambering to tie the knot with multinationals and among themselves in what appears to be a "marriage of necessity" in a desperate attempt to survive a government crackdown on rebates, on which locals have long depended
SEOUL - The Korean government is moving to create a KRW2 trillion ($1.7 billion) research and development fund to help local Korean pharma companies develop globally competitive new drugs
SEOUL - Of the 37 local Korean pharmas listed on Korea's main KOSPI stock market, LG Life Science topped local pharmas in R&D investment last year in both scale and in proportion to its sales, according to a report released by a lawmaker in an Oct. 6 National Assembly session